| Identification | Back Directory | [Name]
Levoemopamil Hydrochloride | [CAS]
101238-54-4 | [Synonyms]
Levemopamil HCl
Levemopamil hydrochloride
(-)-emopamilhydrochloride
(S)-emopamilhydrochloride
Levoemopamil Hydrochloride
(-)-(S)-emopamilhydrochloride
(-)-(S)-2-Isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrilehydrochloride | [Molecular Formula]
C23H31ClN2 | [MOL File]
101238-54-4.mol | [Molecular Weight]
370.97 |
| Hazard Information | Back Directory | [Uses]
Levemopamil hydrochloride is a blood-brain barrier penetrable calcium channel blocker and a 5-HT2 antagonist. Levemopamil hydrochloride can be used for temporary occlusion and neurological disease research[1]. | [in vivo]
Levemopamil hydrochloride (30 mg/kg; i.p., once) regulates bilateral damping of carotid arteries (BCCA) process and reduces spatial memory deficits induced by cerebral oligemia of rats[1]. | Animal Model: | Male Han-Wistar rats with bilateral damping of carotid arteries (BCCA)[1] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal injection; 30 mg/kg, once | | Result: | Showed no effect on GABA or ACh content in either BCCA or sham-operated control rats. Significantly increased swimming speed of BCCA rats in swimming test. Prevented the increasing of escape latency to reach the hidden platform.
|
| [References]
[1] Heim C, et al. Levemopamil injection after cerebral oligemia reduces spatial memory deficits in rats. Pharmacol Biochem Behav. 1994 Jul;48(3):613-9. DOI:10.1016/0091-3057(94)90322-0 |
|
|